MAPK activation predicts poor outcome and the MEK inhibitor, selumetinib, reverses antiestrogen resistance in ER-positive high-grade serous ovarian cancer

Karina E. Hew, Philip C. Miller, Dorraya El-Ashry, Jun Sun, Alexandra H. Besser, Tan A. Ince, Mengnan Gu, Zhi Wei, Gao Zhang, Patricia Brafford, Wei Gao, Yiling Lu, Gordon B. Mills, Joyce M. Slingerland, Fiona Simpkins

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Fingerprint

Dive into the research topics of 'MAPK activation predicts poor outcome and the MEK inhibitor, selumetinib, reverses antiestrogen resistance in ER-positive high-grade serous ovarian cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences